Cargando…

Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders

Detalles Bibliográficos
Autor principal:	Lohoff, Falk W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276049/ https://www.ncbi.nlm.nih.gov/pubmed/30329063 http://dx.doi.org/10.1093/ijnp/pyy087

Ejemplares similares

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
por: O’Connell, Emma M., et al.
Publicado: (2020)

Revisiting the role of raphe and serotonin in neuropsychiatric disorders
por: Adell, Albert
Publicado: (2015)

Gut Microbiota and Neuropsychiatric Disorders
por: Bidaki, Reza, et al.
Publicado: (2023)

Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study
por: Alghamdi, Jahad, et al.
Publicado: (2018)

Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
por: Faridi, Kamil F., et al.
Publicado: (2023)

Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
por: Morofuji, Yoichi, et al.
Publicado: (2022)

Sex Differences in Dopamine Receptors and Relevance to Neuropsychiatric Disorders
por: Williams, Olivia O. F., et al.
Publicado: (2021)

Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder
por: Lohoff, Falk W.
Publicado: (2022)

Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk?
por: Anagnostis, Panagiotis, et al.
Publicado: (2023)

COVID-19 Infection and Risk for Neuropsychiatric Symptoms
por: Bigos, Kristin L., et al.
Publicado: (2022)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
por: Kim, Kyuho, et al.
Publicado: (2022)

Differential susceptibility to plasticity: a 'missing link' between gene-culture co-evolution and neuropsychiatric spectrum disorders?
por: Wurzman, Rachel, et al.
Publicado: (2012)

Mendelian randomization in COVID-19: Applications for cardiovascular comorbidities and beyond
por: Teng, Yaqun, et al.
Publicado: (2020)

Novel Therapeutic Drugs for Neuropsychiatric Disorders
por: Hashimoto, Kenji
Publicado: (2010)

Discoveries in the pathophysiology of neuropsychiatric lupus erythematosus: consequences for therapy
por: Gono, Takahisa, et al.
Publicado: (2013)

The Histaminergic System in Neuropsychiatric Disorders
por: Cheng, Li, et al.
Publicado: (2021)

Stress in Regulation of GABA Amygdala System and Relevance to Neuropsychiatric Diseases
por: Jie, Fan, et al.
Publicado: (2018)

War Psychiatry: Identifying and Managing the Neuropsychiatric Consequences of Armed Conflicts
por: Jain, Nityanand, et al.
Publicado: (2022)

Benefits of Neuropsychiatric Phenomics: Example of the 5-Lipoxygenase-Leptin-Alzheimer Connection
por: Manev, Hari, et al.
Publicado: (2010)

Neuropsychiatric Symptoms and Caregiver Burden in Parkinson's Disease: Mitigating the Lack of Awareness!
por: Nene, Devavrat, et al.
Publicado: (2020)

Beyond Genes: Germline Disruption in the Etiology of Autism Spectrum Disorders
por: Escher, Jill, et al.
Publicado: (2021)

Could androgens be relevant to partly explain why men have lower life expectancy than women?
por: Schooling, C Mary
Publicado: (2016)

Herb-drug Interactions in Neuropsychiatric Pharmacotherapy – A Review of Clinically Relevant Findings
por: Le, Tram T., et al.
Publicado: (2022)

siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy
por: Hu, Bo, et al.
Publicado: (2023)

Beyond lipid lowering: pleiotropic effects of statins in heart failure
por: Swenne, C. A.
Publicado: (2013)

Neuropsychiatric Effects of Antiviral Drugs
por: Zareifopoulos, Nicholas, et al.
Publicado: (2020)

The Multiple Realizability of Sentience in Living Systems and Beyond
por: Rouleau, Nicolas, et al.
Publicado: (2023)

COPD and Asthma: Effects Beyond the Respiratory System
por: Barnes, Peter J.
Publicado: (2012)

Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations
por: Zorkina, Yana, et al.
Publicado: (2020)

The importance of improving health literacy to lower cardiovascular risk in type 2 diabetes
por: Hansen, Dominique, et al.
Publicado: (2019)

The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
por: Kalra, Sanjay, et al.
Publicado: (2016)

Neuropsychiatric Symptoms in Parkinson’s Disease: Beyond Complications
por: Kehagia, Angie A.
Publicado: (2016)

Prescription Opioid Use and Risk for Major Depressive Disorder and Anxiety and Stress-Related Disorders: A Multivariable Mendelian Randomization Analysis
por: Rosoff, Daniel B., et al.
Publicado: (2020)

It is time to progress beyond the System 1 versus System 2 dichotomy
por: Rotgans, Jerome I.
Publicado: (2015)

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
por: Michaeli, Daniel Tobias, et al.
Publicado: (2023)

Neuropsychiatric consequences of cardiovascular medications
por: Huffman, Jeff C., et al.
Publicado: (2007)

Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling
por: Ali, Moazzam, et al.
Publicado: (2017)

Beyond post-marketing research and MedWatch: Long-term studies of drug risks
por: Resnik, David B
Publicado: (2007)

Beyond new chemical entities: Advancing drug development based on functional versatility of antibodies
por: Caoili, Salvador Eugenio C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h3ou6ni8nncle2b4s7r4np1d20